After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro ...
Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results